Search PubMed⌕ Search

Biomedical subjects

M I Gluckman

Publications and source records attributed to M I Gluckman.

At least 19 recordsLinked to original sources

The topical anti-inflammatory effects of a topical preparation of meclofenamic acid on carrageenan-induced footpad swelling in mice.

A topical preparation of meclofenamic acid (Meclomen) was tested for anti-inflammatory activity in a murine model of carrageenan footpad oedema. The preparation significantly inhibited swelling when applied to the carrageenan-injected paw. Maximum inhibition was observed 4-5 h after carrageenan injection. The topical effects could not be attributed to systemic absorption because the preparation was more inhibitory when applied topically to the carrageenan-injected paw than to a distant site or orally.

Administration, Oral↗

Isoxicam.

Explore the source record for details and available documents.

Adult↗

On the mechanism of the pharmacologic activity of meclofenamate sodium.

N-(2,6-Dichloro-m-tolyl)anthranilic acid, sodium salt (meclofenamate sodium, Meclomen), the sodium salt of meclofenamic acid, has anti-inflammatory activity both in animal models and in clinical use. This activity is believed to be due in large part to the ability of the drug to inhibit the synthesis of prostaglandins by inhibiting arachidonic acid cyclo-oxygenase. Further, there is evidence that meclofenamic acid directly antagonizes the actions of prostaglandins at receptor sites. In addition, meclofenamic acid may also inhibit arachidonic acid lipoxygenase, resulting in decreased synthesis of leukotrienes, known mediators involved in the inflammatory process.

Animals↗

Pharmacology of lorazepam.

Lorazepam reduced conflict behavior in rats and monkeys, inhibited pentylenetetrazol- and electroshock-induced convulsions, suppressed footshock-induced fighting behavior, and prevented morphine-induced stimulation in mice at lower doses than other benzodiazepines tested. This behavioral profile suggests that lorazepam will be an active anti-anxiety agent in man at low doses.

Aggression↗

Immunopharmacologic properties of WY-16,922, a new orally effective antiallergic agent.

In a series of tests designed to illustrate immune reactions similar to those obtained in atopic disease, Wy-16,922 effectively inhibited reaginic-mediated immunologic reactions in the skin, longs and mast cell. It was found to be devoid of immunosuppressant, antimediator, anti-inflammatory, steroid or bronchodilator properties as well as acute toxicity. Although the mechanism of action Wy-16,922 is unknown, it appears to limit the release (not the effects) of allergic mediators in a manner similar to that described for disodium cromoglycate.

Anaphylaxis↗

Immunopharmacologic properties of WY-16, 922, a new orally effective antiallergic agent.

In a series of tests designed to illustrate immune reactions similar to those obtained in atopic disease, Wy-16,922 effectively inhibited reaginic-mediated immunologic reactions in the skin, lungs and mast cell. It was found to be devoid of immunosuppressant, antimediator, anti-inflammatory, steroid or bronchodilator properties as well as acute toxicity. Although the mechanism of action of Wy-16,922 is unknown, it appears to limit the release (not the effects) of allergic mediators in a manner similar to that described for disodium cromoglycate.

Anaphylaxis↗

Animal pharmacology of Wy-16,225, a new analgesic agent.

The analgesic potency of Wy-16,225 in rodents and primates is greater than morphine while antagonist potency is slightly less than that of nalorphine. The compound demonstrates properties unlike those of standard narcotic and narcotic antagonist agents and has a wide margin of safety. In dependence liability studies, Wy-16,225 neither acutely substitutes for morphine nor produces direct dependence when administered chronically to monkeys. Wy-16,225 has no anti-inflammatory properties, is not constipating in rats, has no significant cardiovascular toxicity in dogs and produces minimal respiratory depression in monkeys.

Analgesics↗